Cargando…

Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher Disease

OBJECTIVE: To report the association between type 1 Gaucher disease (GD1) and amyotrophic lateral sclerosis (ALS) in 3 unrelated families and to explore whether GBA variants influence the risk of ALS. METHODS: We conducted retrospective chart reviews of patients with GD1 or their family members diag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oliveira, Lais M., Rastin, Tara, Nimmo, Graeme A.M., Ross, Jay P., Dion, Patrick A., Zhang, Ming, Nevay, Dayna-Lynn, Arkadir, David, Gotkine, Marc, Barnett, Carolina, Shoesmith, Christen L., Zimran, Ari, Rogaeva, Ekaterina A., Zinman, Lorne, Rouleau, Guy A., Gan-Or, Ziv, Amato, Dominick, Kalia, Lorraine V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130998/ https://www.ncbi.nlm.nih.gov/pubmed/34017912 http://dx.doi.org/10.1212/NXG.0000000000000600

Ejemplares similares

Simultaneous Bilateral Femoral Osteonecrosis in Gaucher Disease
por: Cohen, Daniel, et al.
Publicado: (2023)

Long Term Follow-Up of 103 Untreated Adult Patients with Type 1 Gaucher Disease
por: Dinur, Tama, et al.
Publicado: (2019)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Macular Ganglion Cell Complex and Peripapillary Retinal Nerve Fiber Layer Thinning in Patients with Type-1 Gaucher Disease
por: Weill, Yishay, et al.
Publicado: (2020)

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease
por: Elstein, Deborah, et al.
Publicado: (2009)

Neuropathologic description of CHCHD10 mutated amyotrophic lateral sclerosis
por: Keith, Julia L., et al.
Publicado: (2020)

Dental profile of patients with Gaucher disease
por: Fischman, Stuart L, et al.
Publicado: (2003)

De novo FUS P525L mutation in Juvenile amyotrophic lateral sclerosis with dysphonia and diplopia
por: Leblond, Claire S., et al.
Publicado: (2016)

Low molecular weight species of TDP-43 generated by abnormal splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death
por: Xiao, Shangxi, et al.
Publicado: (2015)

A Comprehensive Assessment of Qualitative and Quantitative Prodromal Parkinsonian Features in Carriers of Gaucher Disease—Identifying Those at the Greatest Risk
por: Becker-Cohen, Michal, et al.
Publicado: (2022)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
por: Schwartz, Ida Vanessa D., et al.
Publicado: (2017)

Amyotrophic lateral sclerosis: new genes, new models, and new mechanisms
por: Vande Velde, Christine, et al.
Publicado: (2011)

Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
por: Pastores, Gregory M., et al.
Publicado: (2016)

Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2016)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Homozygous N396T mutation in Gaucher disease: Portuguese sisters with markedly different phenotypes
por: Kimball, Samantha, et al.
Publicado: (2011)

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)
por: Zimran, Ari, et al.
Publicado: (2017)

Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports
por: Amato, Dominick, et al.
Publicado: (2018)

Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review
por: Revel-Vilk, Shoshana, et al.
Publicado: (2020)

Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2018)

Three cases of multi-generational Gaucher disease and colon cancer from an Ashkenazi Jewish family: A lesson for cascade screening
por: Hannah-Shmouni, Fady, et al.
Publicado: (2019)

Clinical course and prognosis in patients with Gaucher disease and parkinsonism
por: Lopez, Grisel, et al.
Publicado: (2016)

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)
por: Yunusova, Yana, et al.
Publicado: (2011)

Poor results of drilling in early stages of juxta-articular osteonecrosis in 12 joints affected by Gaucher disease
por: Lebel, Ehud, et al.
Publicado: (2009)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Somatic expansion of the C9orf72 hexanucleotide repeat does not occur in ALS spinal cord tissues
por: Ross, Jay P., et al.
Publicado: (2019)

Achievement of Therapeutic Goals with Low-Dose Imiglucerase in Gaucher Disease: A Single-Center Experience
por: Tukan, Irina, et al.
Publicado: (2013)

Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2022)

Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative
por: Mehta, Atul, et al.
Publicado: (2019)

Retinal Spheroids and Axon Pathology Identified in Amyotrophic Lateral Sclerosis
por: Sharma, Kieran, et al.
Publicado: (2020)

Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
por: Hughes, Derralynn A., et al.
Publicado: (2023)

Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease
por: Dinur, Tama, et al.
Publicado: (2020)

Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease
por: Dinur, Tama, et al.
Publicado: (2023)

Seven‐year safety and efficacy with velaglucerase alfa for treatment‐naïve adult patients with type 1 Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2015)

Brain-Derived Neurotrophic Factor (BDNF) Is Associated with Platelet Activity and Bleeding Tendency in Patients with Gaucher Disease
por: Azoulay, David, et al.
Publicado: (2022)

Questioning the Association of the STMN2 Dinucleotide Repeat With Amyotrophic Lateral Sclerosis
por: Ross, Jay P., et al.
Publicado: (2022)

Breached Barriers: A Scoping Review of Blood-Central Nervous System Barrier Pathology in Amyotrophic Lateral Sclerosis
por: Mirian, Ario, et al.
Publicado: (2022)

P1633: LOW SERUM BDNF LEVELS ARE ASSOCIATED WITH LOWER PLATELETS’ CD62P REACTIVITY AND INCREASED BLEEDING TENDENCY IN PATIENTS WITH GAUCHER DISEASE
por: Azoulay, D., et al.
Publicado: (2022)

Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients
por: Rolfs, Arndt, et al.
Publicado: (2013)

Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease
por: Charkhand, Behshad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e3n09p620m4nrl5j9fq0v75d8p